Thursday, November 12, 2026

How We Source Explore Search

#BIOTECH

25 articles

Biotech Grows Up: A Phase 3 Win, a Profitable Incyte and Royalty Income, While the Early Pipeline and AI Drugs Still Have to Prove Themselves

Biotech Grows Up: A Phase 3 Win, a Profitable Incyte and Royalty Income, While the Early Pipeline and AI Drugs Still Have to Prove Themselves

LM Salvado•Nov 2, 2026

Oncology's Busy Autumn: A Cash-Burning Drugmaker Awaits Its Verdict While AI Promises Faster Medicines

Oncology's Busy Autumn: A Cash-Burning Drugmaker Awaits Its Verdict While AI Promises Faster Medicines

LM Salvado•Oct 15, 2026

Oncology's Q4 Decision Window: Three Dated Catalysts, One Already Delivered, and a Sector Splitting Between Cash-Rich and Cash-Careful

Oncology's Q4 Decision Window: Three Dated Catalysts, One Already Delivered, and a Sector Splitting Between Cash-Rich and Cash-Careful

LM Salvado•Oct 11, 2026

Cancer's two big bets: a personalised vaccine that held melanoma at bay, and AI that designs the drugs. Here is what is verified and what is not

Cancer's two big bets: a personalised vaccine that held melanoma at bay, and AI that designs the drugs. Here is what is verified and what is not

LM Salvado•Oct 3, 2026

NVIDIA GPU Power Fuels Global Boom in AI Drug Discovery Startups

NVIDIA GPU Power Fuels Global Boom in AI Drug Discovery Startups

LM Salvado•Aug 8, 2026

Denmark's Novo Nordisk Outsources Drug R&D as US Firms Patent the AI Layer Beneath Biology

Science & Technology

Denmark's Novo Nordisk Outsources Drug R&D as US Firms Patent the AI Layer Beneath Biology

LM Salvado•Jul 23, 2026

Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar

Biotech & Pharma

Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar

LM Salvado•Jun 19, 2026

FDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell Therapies

Pharmaceuticals & Biotech

FDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell Therapies

LM Salvado•Jun 17, 2026

Eli Lilly Crosses $20B in 2026 Acquisitions as AI Rewrites Pharma's Global Deal Logic

Business & Finance

Eli Lilly Crosses $20B in 2026 Acquisitions as AI Rewrites Pharma's Global Deal Logic

LM Salvado•May 31, 2026

Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents

Biotech & Pharma

Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents

LM Salvado•May 27, 2026

Novo Nordisk Shares Surge 24.9% as Global Pharma Abandons Wet Labs for AI

Health & Science

Novo Nordisk Shares Surge 24.9% as Global Pharma Abandons Wet Labs for AI

LM Salvado•May 13, 2026

Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals

Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals

LM Salvado•Apr 18, 2026

U.S. Rare Disease Drugmaker Faces $200M Revenue Loss as Patent Cliff Looms in 2035

Healthcare & Pharmaceuticals

U.S. Rare Disease Drugmaker Faces $200M Revenue Loss as Patent Cliff Looms in 2035

ViaNews Editorial Team•Mar 12, 2026

Artiva Biotherapeutics faces $50-150M capital gap as NK cell therapy trials advance

Artiva Biotherapeutics faces $50-150M capital gap as NK cell therapy trials advance

ViaNews Editorial Team•Mar 7, 2026

Cardiff Oncology's $60M Cash Reserve Gives Five Quarters Before Funding Crisis

Cardiff Oncology's $60M Cash Reserve Gives Five Quarters Before Funding Crisis

ViaNews Editorial Team•Mar 7, 2026

Cardiff Oncology's $500M+ valuation at risk as cancer trial targeting 40-50% of colorectal cases nears Q1 2026 data release

Cardiff Oncology's $500M+ valuation at risk as cancer trial targeting 40-50% of colorectal cases nears Q1 2026 data release

ViaNews Editorial Team•Mar 7, 2026

Biotech Funding Drought Puts $300M Ophthalmology Drug at Risk of Capital Collapse

Biotech Funding Drought Puts $300M Ophthalmology Drug at Risk of Capital Collapse

ViaNews Editorial Team•Mar 1, 2026

Biotech Kyntra Bio Risks 60-80% Wipeout as Single Cancer Drug FG-3246 Faces Trial Verdict

pharmaceuticals

Biotech Kyntra Bio Risks 60-80% Wipeout as Single Cancer Drug FG-3246 Faces Trial Verdict

ViaNews Editorial Team•Feb 26, 2026

Zevra Therapeutics risks collapse as 90% revenue depends on single rare disease drug

Zevra Therapeutics risks collapse as 90% revenue depends on single rare disease drug

ViaNews Editorial Team•Feb 25, 2026

LeonaBio Risks $140M Market Cap on Single Breast Cancer Trial After Neurodegenerative Pivot

LeonaBio Risks $140M Market Cap on Single Breast Cancer Trial After Neurodegenerative Pivot

ViaNews Editorial Team•Feb 22, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring

A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,995

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,995 facts checked against source5,565 source documents archived

Query this data → isubstrate.com